Xu Tingjuan, Shen Guodong, Cheng Min, Xu Weiping, Shen Gan, Hu Shilian
Gerontology Institute of Anhui Province, Anhui Provincial Hospital Affiliated Anhui Medical University, Hefei 230001, China.
Anhui Provincial Key Laboratory of Tumor Immunotherapy and Nutrition Therapy, Hefei 230001, China.
Oncotarget. 2017 Jul 10;8(37):62524-62536. doi: 10.18632/oncotarget.19122. eCollection 2017 Sep 22.
The prognostic significance of circulating tumor cells in patients with lung cancer is controversial. Therefore, we aimed to comprehensively and quantitatively assess the prognostic role of CTCs in patients with lung cancer.
The relevant literature was searched using PubMed, the Cochrane database and the China National Knowledge Internet database (up to June 2016). Using Review Manager 5.1.2, a meta-analysis was performed using hazard ratio (HR), odds ratio (OR) and 95% confidence interval (CI) as effect values.
Thirty studies comprising 2,060 patients with lung cancer were analyzed. The pooled HR values showed that circulating tumor cells were significantly correlated with overall survival (HR =2.63, 95% CI [2.04, 3.39]) and progression-free survival (HR =3.74, 95% CI [2.49, 5.61]) in these patients. Further subgroup analyses were conducted and categorized by sampling time, detection method, and histological type; these analyses showed the same trend. The pooled OR values showed that circulating tumor cells were associated with non small cell lung cancer stage(OR = 2.11, 95% CI [1.42, 3.14]), small cell lung cancer stage (OR = 10.91, 95% CI [4.10, 29.06]), distant metastasis (OR =7.06, 95%CI [2.82, 17.66]), lymph node metastasis (OR =2.31, 95% CI [1.19,4.46]), and performance status(OR =0.42, 95%CI [0.22, 0.78]).
The detection of circulating tumor cells in the peripheral blood of patients with lung cancer can be indicative of a poor prognosis.
循环肿瘤细胞在肺癌患者中的预后意义存在争议。因此，我们旨在全面、定量地评估循环肿瘤细胞在肺癌患者中的预后作用。
使用PubMed、Cochrane数据库和中国知网数据库（截至2016年6月）检索相关文献。使用Review Manager 5.1.2进行荟萃分析，以风险比（HR）、比值比（OR）和95%置信区间（CI）作为效应值。
分析了30项研究，共纳入2060例肺癌患者。汇总的HR值显示，循环肿瘤细胞与这些患者的总生存期（HR = 2.63，95% CI [2.04, 3.39]）和无进展生存期（HR = 3.74，95% CI [2.49, 5.61]）显著相关。进一步按采样时间、检测方法和组织学类型进行亚组分析；这些分析显示出相同趋势。汇总的OR值显示，循环肿瘤细胞与非小细胞肺癌分期（OR = 2.11，95% CI [1.42, 3.14]）、小细胞肺癌分期（OR = 10.91，95% CI [4.10, 29.06]）、远处转移（OR = 7.06，95% CI [2.82, 17.66]）、淋巴结转移（OR = 2.31，95% CI [1.19, 4.46]）和体能状态（OR = 0.42，95% CI [0.22, 0.78]）相关。
检测肺癌患者外周血中的循环肿瘤细胞可提示预后不良。
